Industry ยท Oct 2026
General Drug Manufacturer stocks ranked by gap to the model's fair value
Faircurve's model values 10 general drug manufacturer stocks. 9 of them are ranked below by the gap between the model's fair value and the last close, as of 31 Oct 2026: 0 read as Undervalued, 8 as Fairly valued and 1 as Overvalued. The median gap across the ranked names is +3.9%. The widest gaps above the price are BMY (+14.5%), PFE (+13.5%), AMGN (+6.5%). The widest below it are LLY (-20.9%), JNJ (-14.6%), MRK (-13.0%).
Valuations as of . Prices are the closes of 3 Nov 2026. The gap is the model's fair value against the price: a positive gap means the fair value is above the price. It states what the model concluded, not where the price goes next.
The ranking
| Rank | Company | Last close | Model fair value | Gap | Model verdict | Quality score | Market value |
|---|---|---|---|---|---|---|---|
| 1 | BMY Bristol-Myers Squibb Company | $61.71 | $70.65 | +14.5% | Fairly valued | 34 | $127.6B |
| 2 | PFE Pfizer Inc. | $30.00 | $34.04 | +13.5% | Fairly valued | 32 | $174.0B |
| 3 | AMGN Amgen Inc. | $461.26 | $491.10 | +6.5% | Fairly valued | 67 | $251.9B |
| 4 | ABBV AbbVie Inc. | $286.00 | $297.68 | +4.1% | Fairly valued | 78 | $521.1B |
| 5 | BIIB Biogen Inc. | $248.93 | $258.65 | +3.9% | Fairly valued | 48 | $37.5B |
| 6 | GILD Gilead Sciences, Inc. | $167.47 | $157.69 | -5.8% | Fairly valued | 41 | $211.6B |
| 7 | MRK Merck & Co., Inc. | $144.67 | $125.88 | -13.0% | Fairly valued | 40 | $368.9B |
| 8 | JNJ Johnson & Johnson | $266.17 | $227.23 | -14.6% | Fairly valued | 67 | $657.7B |
| 9 | LLY Eli Lilly and Company | $1,409.38 | $1,114.95 | -20.9% | Overvalued | 71 | $1.33T |
The Global Pulse
Faircurve's market note, in your inbox each market day
The Global Pulse is Faircurve's note after each US session: what moved, in plain words. No account needed.
Valued but not ranked
One name is valued but not ranked, for one of four reasons: the model grades the evidence as low or has not graded it yet, the inputs are under review, the gap is wider than 60%, or the valuation is more than three weeks old. The numbers are shown for reference.
| Company | Last close | Model fair value | Gap | Why it is not ranked | Quality score | Market value |
|---|---|---|---|---|---|---|
| OGN Organon & Co. | $13.85 | $13.90 | +0.4% | Low evidence grade | $3.6B |